

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Novogen Limited ("Novogen")
ABN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr John P O'Connor
Date of last notice	3/6/2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	A. Indirect B. Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	A. Aspargo Pty Ltd - Director B. Mr John P O'Connor	
Date of change	4/6/2015	
No. of securities held prior to change	A. 258,071 ordinary shares B. 20,530 ordinary shares Total = 278,601 ordinary shares	
Class	Ordinary shares Unlisted options	
Number acquired	A 43,012 ordinary shares 64,519 unlisted options	B 3,422 ordinary shares 5,133 unlisted options
Number disposed	N/A	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.30 per ordinary share Total consideration \$13,930.20 Options for no consideration as part of the entitlement offer announced on 21 April 2015
No. of securities held after change	A 301,083 ordinary shares 43,012 unlisted options expiring 4/12/2015 with an exercise price of \$0.30 per option 21,507 unlisted options expiring 4/06/2020 with an exercise price of \$0.40 per option B 23,952 ordinary shares 3,422 unlisted options expiring 4/12/2015 with an exercise price of \$0.30 per option 1,711 unlisted options expiring 4/06/2020 with an exercise price of \$0.40 per option TOTAL 325,035 ordinary shares 69,652 Unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Allocation of entitlement following rights issue, as announced 21 April 2015, which included shares and options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Novogen Limited ("Novogen")
ABN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Steven R Coffey
Date of last notice	04/05/2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Steven Roy Coffey Superannuation Fund (Steven and Sandra Coffey as trustee)
Date of change	4/6/2015
No. of securities held prior to change	560,966 ordinary shares 144,000 unlisted options
Class	A. Ordinary shares B. Unlisted options
Number acquired	A. 117,494 ordinary shares B. 176,241 unlisted options
Number disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.30 per ordinary share Total consideration \$35,248.20 Options for no consideration as part of the entitlement offer announced on 21 April 2015
No. of securities held after change	678,460 ordinary shares 144,000 unlisted options with exercise price of \$0.125 per option, expiring 18/11/2015 117,494 unlisted options with exercise price of \$0.30 per option, expiring 4/12/2015 58,747 unlisted options with exercise price of \$0.40 per option, expiring 4/06/2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Allocation of entitlement following rights issue, as announced 21 April 2015, which included shares and options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Novogen Limited ("Novogen")
ABN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Graham Kelly
Date of last notice	16/01/2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	A. Indirect B. Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	A 1. Phytose Corporation Pty Ltd 2. Phytose Corporation Pty Ltd Staff Super Fund Account 3. Bende Holding Pty Ltd B 1. Mr Graham Kelly 2. Dr Graham Kelly
Date of change	4/6/2015
No. of securities held prior to change	A <u>Phytose Corporation Pty Ltd</u> 3,706,025 ordinary shares 181,818 unlisted options <u>Phytose Corporation Pty Ltd Staff Super Fund Account</u> 7,000 ordinary shares <u>Bende Holding Pty Ltd</u> 1,677,432 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	B <u>Mr Graham Kelly</u> 10,000 ordinary shares <u>Dr Graham Kelly</u> 90,000 ordinary shares
	TOTAL 5,490,367 ordinary shares 181,818 unlisted options
Class	Ordinary shares Unlisted options
Number acquired	A. 117,494 ordinary shares B. 176,241 unlisted options
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.30 per ordinary share Total consideration \$34,500 Options for no consideration as part of the entitlement offer announced on 21 April 2015
No. of securities held after change	A <u>Phytose Corporation Pty Ltd</u> 3,806,025 ordinary shares 181,818 unlisted options expiring 18/11/15, with exercise price of \$0.125 per option 100,000 unlisted options expiring 4/12/2015 with exercise price of \$0.30 per option 50,000 unlisted options expiring 4/6/2015 with exercise price of \$0.40 per option <u>Phytose Corporation Pty Ltd Staff Super Fund Account</u> 7,000 ordinary shares <u>Bende Holding Pty Ltd</u> 1,677,432 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	B <u>Mr Graham Kelly</u> 10,000 ordinary shares <u>Dr Graham Kelly</u> 105,000 ordinary shares 15,000 unlisted options expiring 4/12/2015 with exercise price of \$0.30 per option 7,500 unlisted options expiring 4/6/2015 with exercise price of \$0.40 per option
	TOTAL 5,605,367 ordinary shares 354,318 unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Allocation of entitlement following rights issue, as announced 21 April 2015, which included shares and options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.